Targeting ferroptosis opens new avenues for the development of novel therapeutics

被引:181
|
作者
Sun, Shumin [1 ]
Shen, Jie [1 ]
Jiang, Jianwei [1 ]
Wang, Fudi [1 ]
Min, Junxia [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Affiliated Hosp 2,Sch Med, Inst Translat Med,Canc Ctr,Sch Publ Hlth,State Ke, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
GLUTATHIONE-PEROXIDASE; 4; ERASTIN-INDUCED FERROPTOSIS; POLYUNSATURATED FATTY-ACIDS; TRANSFERRIN-BOUND-IRON; CELL-DEATH MECHANISMS; LIPID-PEROXIDATION; SMALL-MOLECULE; CANCER-CELLS; IN-VIVO; MITOCHONDRIAL DYSFUNCTION;
D O I
10.1038/s41392-023-01606-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ferroptosis is an iron-dependent form of regulated cell death with distinct characteristics, including altered iron homeostasis, reduced defense against oxidative stress, and abnormal lipid peroxidation. Recent studies have provided compelling evidence supporting the notion that ferroptosis plays a key pathogenic role in many diseases such as various cancer types, neurodegenerative disease, diseases involving tissue and/or organ injury, and inflammatory and infectious diseases. Although the precise regulatory networks that underlie ferroptosis are largely unknown, particularly with respect to the initiation and progression of various diseases, ferroptosis is recognized as a bona fide target for the further development of treatment and prevention strategies. Over the past decade, considerable progress has been made in developing pharmacological agonists and antagonists for the treatment of these ferroptosis-related conditions. Here, we provide a detailed overview of our current knowledge regarding ferroptosis, its pathological roles, and its regulation during disease progression. Focusing on the use of chemical tools that target ferroptosis in preclinical studies, we also summarize recent advances in targeting ferroptosis across the growing spectrum of ferroptosis-associated pathogenic conditions. Finally, we discuss new challenges and opportunities for targeting ferroptosis as a potential strategy for treating ferroptosis-related diseases.
引用
收藏
页数:30
相关论文
共 50 条
  • [31] A Structural Model of the Staphylococcus aureus ClfA-Fibrinogen Interaction Opens New Avenues for the Design of Anti-Staphylococcal Therapeutics
    Ganesh, Vannakambadi K.
    Rivera, Jose J.
    Smeds, Emanuel
    Ko, Ya-Ping
    Bowden, M. Gabriela
    Wann, Elisabeth R.
    Gurusiddappa, Shivasankarappa
    Fitzgerald, J. Ross
    Hoeoek, Magnus
    PLOS PATHOGENS, 2008, 4 (11)
  • [32] Nitroarenes: The rediscovery of their photochemistry opens new avenues in organic synthesis
    Gkizis, Petros L.
    Triandafillidi, Ierasia
    Kokotos, Christoforos G.
    CHEM, 2023, 9 (12): : 3401 - 3414
  • [33] Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
    Michielsen, Adriana J.
    O'Sullivan, Jacintha N.
    Ryan, Elizabeth J.
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2010, 4 (02) : 146 - 152
  • [34] Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
    Sharma, Horrick
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (06) : 505 - 524
  • [35] TRANSITION TECHNOLOGY OPENS NEW INDUSTRIAL I/O AVENUES
    BARTOS, FJ
    CONTROL ENGINEERING, 1988, 35 (11) : 86 - 87
  • [36] Ocriplasmin opens up new avenues in the therapy of vitreomacular traction
    Schmit-Eilenberger, Vera K.
    Augustin, Albert J.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2013, 8 (05) : 407 - 411
  • [37] Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
    Machado-Vieira, Rodrigo
    Salvadore, Giacomo
    Ibrahim, Lobna A.
    Diaz-Granados, Nancy
    Zarate, Carlos A., Jr.
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (14) : 1595 - 1611
  • [38] Inhibiting ferroptosis: A novel approach for stroke therapeutics
    Jin, Yizhen
    Zhuang, Yuxin
    Liu, Mei
    Che, Jinxin
    Dong, Xiaowu
    DRUG DISCOVERY TODAY, 2021, 26 (04) : 916 - 930
  • [39] Targeting Diabetes and Novel Therapeutics
    Sullivan, Patrick G.
    JOURNAL OF DIABETES & METABOLISM, 2015, 6
  • [40] Early phase trials of novel hearing therapeutics: Avenues and opportunities
    Schilder, Anne G. M.
    Su, Matthew P.
    Mandavia, Rishi
    Anderson, Caroline R.
    Landry, Evie
    Ferdous, Tanjinah
    Blackshaw, Helen
    HEARING RESEARCH, 2019, 380 : 175 - 186